MedTrace Logo

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

NCT01506167 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 719

Last updated 2018-05-14

No results posted yet for this study

Summary

This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no previous treatment for advanced disease and are receiving Avastin in combination with a standard of care first-line chemotherapy regimen. Data will be collected for 1.5 years or until death.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab was administered as part of standard first-line treatment

DRUG

Capecitabine/Oxaliplatin

Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment

DRUG

Fluorouracil/Folinic Acid/Oxaliplatin

Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment

DRUG

Capecitabine

Capecitabine was administered along with bevacizumab as part of standard first-line treatment

DRUG

Fluorouracil/Folinic Acid/Irinotecan

Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment

DRUG

Fluorouracil +/- Folinic Acid

Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-06
Primary Completion
2017-03-10
Completion
2017-03-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506167 on ClinicalTrials.gov